Jason Christiansen

Jason Christiansen, Ph.D., joins Epic Sciences as CTO bringing 20 years of experience in developing new technologies and the strategies for their uses in research, clinical diagnostics and targeted therapy development. Jason joins Epic from Boundless Bio, where he served as CTO and oversaw development of methods for the identification and characterization of extrachromosomal DNA; combining biological visualization, image analysis and structural biology to identify specific tumor types and patient populations. Prior to that, he was the head of assay development at Roche Sequencing Solutions, providing leadership in initiatives around oncology testing, diagnostics development, NIPT testing and platform development. Jason was vice president of diagnostics at Ignyta, later purchased by Roche/Genentech, where he led CDx development strategies and implementation, including an on-site CLIA laboratory and molecular testing R&D group working both internally and externally to drive molecular testing in support of a global clinical trial for Rozlytrek (entrectinib). These efforts produced one of the earliest Expedited Access Pathway (Breakthrough Diagnostic) designations for the Ignyta RNA next generation sequencing test. As the senior director of assay development at Genoptix (Novartis), Jason led efforts to introduce new technology products, including NGS and digital pathology (routine and immunofluorescence), into the clinical laboratory for commercial and pharma applications. At HistoRx, Jason was a leader in the development of a quantitative immunofluorescence imaging platform, including assay, hardware, and software components, for clinical diagnostic testing and pharma applications.